Shares of Black Diamond Therapeutics Inc. (BDTX) are up nearly 40% at $2.34 in premarket trading today, on news of the company entering into a strategic worldwide licensing agreement for its investigational drug BDTX-4933, with Servier, an independent global pharmaceutical group governed by a non-profit foundation.
BDTX-4933, designed to target RAS and RAF alterations in solid tumors, is currently in phase I development.
For comments and feedback contact: editorial@rttnews.com
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.